David Hallal is Co-Founder, Chairman and CEO of ElevateBio, and a 30-year veteran in the biopharmaceutical industry, with expertise in early-stage company building as well as operating large multinational biotech companies. He also serves as Chairman of Scholar Rock (Nasdaq: SRRK), Chairman of iTeos Therapeutics (Nasdaq: ITOS), Chairman of Kalaris (Nasdaq: KLRS), and is lead independent director of Seer Biosciences (Nasdaq: SEER). Previously, he spent more than a decade at Alexion Pharmaceuticals, where he served as CEO, COO, and CCO, playing a pivotal role in transforming the company from a pre-commercial stage in 2006 to over $3 billion in annual revenue by 2016. As CEO, he led the transition from a single-product company to a multi-product enterprise, driving approvals and launches in the US, EU, and Japan—including Strensiq® and the rapid advancement of Ultomiris® from preclinical to registration trials within 18 months. Earlier, as CCO and COO, he built a 50-country commercial platform and led the global launch of Soliris® for ultra-rare diseases, achieving one of the industry’s most successful ultra-orphan drug commercializations. Prior to Alexion, David held senior commercial roles at OSI Eyetech, Biogen, and Amgen, where he was instrumental in launching and expanding adoption of several first-in-class and blockbuster therapies across hematology, oncology, nephrology, immunology, and ophthalmology. David holds a BA in psychology from the University of New Hampshire.